Epidemics

FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot AloneFluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot Alone

FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot Alone

– Findings reported today in the journal Lancet Infectious Diseases– Study shows synergistic immunological response generated by M2SR and Fluzone High…

11 months ago
Journey Medical Corporation Appoints Michael C. Pearce to Board of DirectorsJourney Medical Corporation Appoints Michael C. Pearce to Board of Directors

Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that…

11 months ago
A Single Drug Against Multiple Respiratory Virus Infections – COVID, RSV, Influenza, Bird Flu – Planning Next Phase of Clinical Trials, Says NanoViricidesA Single Drug Against Multiple Respiratory Virus Infections – COVID, RSV, Influenza, Bird Flu – Planning Next Phase of Clinical Trials, Says NanoViricides

A Single Drug Against Multiple Respiratory Virus Infections – COVID, RSV, Influenza, Bird Flu – Planning Next Phase of Clinical Trials, Says NanoViricides

SHELTON, CT / ACCESSWIRE / July 11, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader…

11 months ago
Sapiens Accelerates Growth for Medical Professional Liability InsurersSapiens Accelerates Growth for Medical Professional Liability Insurers

Sapiens Accelerates Growth for Medical Professional Liability Insurers

Sapiens' expanded offering maximizes business value for MPL insurers, supporting growth and retention   ROCHELLE PARK, N.J., July 2, 2024…

11 months ago
Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell LymphomaOdronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Recommendation based on data from the Phase 1 and pivotal Phase 2 trials demonstrating robust and durable response rates in…

11 months ago
Leaders convene to pursue solutions to Wildlife Data Sharing, Bridging the wildlife sector with world-class science to prevent the next pandemicLeaders convene to pursue solutions to Wildlife Data Sharing, Bridging the wildlife sector with world-class science to prevent the next pandemic

Leaders convene to pursue solutions to Wildlife Data Sharing, Bridging the wildlife sector with world-class science to prevent the next pandemic

SEATTLE, June 20, 2024 /PRNewswire/ -- Even as the role of wildlife in disease outbreaks is increasingly recognized, our ability to…

12 months ago
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of DirectorsJasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company…

12 months ago
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanomaImmunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma

Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of…

12 months ago
Goodness Growth Holdings Announces Closing of Recently Announced Non-Brokered Private PlacementGoodness Growth Holdings Announces Closing of Recently Announced Non-Brokered Private Placement

Goodness Growth Holdings Announces Closing of Recently Announced Non-Brokered Private Placement

– Company also receives short extension of its credit agreement until July 31, 2024 –MINNEAPOLIS, June 17, 2024 (GLOBE NEWSWIRE)…

12 months ago
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple MyelomaUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma

Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma

At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71%…

12 months ago
Show more Posts
Show previous Posts